PAS
VRTX icon

PKS Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History

PKS Advisory Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-453
Closed -$205K – 263
2025
Q4 		$205K Buy
+453
New +$195K 0.05% 244
2025
Q3 		– Sell
-465
Closed -$207K – 283
2025
Q2 		$207K Buy
+465
New +$214K 0.05% 245
2025
Q1 		– Sell
-595
Closed -$240K – 272
2024
Q4 		$240K Buy
+595
New +$276K 0.06% 211

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

PKS Advisory Services's VRTX Position: Q1 2026 in Review

PKS Advisory Services sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 453 shares — an estimated $205K sold.

PKS Advisory Services first reported a position in VRTX in Q4 2024 and held it in 3 quarters. The position peaked at $240K in Q4 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • PKS Advisory Services reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • PKS Advisory Services sold 453 Vertex Pharmaceuticals shares in Q1 2026, an estimated $205K.
  • PKS Advisory Services first reported a position in Vertex Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • PKS Advisory Services's Vertex Pharmaceuticals position peaked at $240K in Q4 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on PKS Advisory Services's 13F filing for Q1 2026, filed 13 May 2026.